• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Galmed Pharmaceutica (NQ: GLMD )

    3.910 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 9, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 3.910
    Bid (Size) 3.900 (26)
    Ask (Size) 4.200 (1)
    Prev. Close 3.910
    Today's Range 3.910 - 3.910
    52wk Range 2.730 - 23.80
    Shares Outstanding 6,358,747
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank?
    A look at the 20 most searched tickers on Benzinga Pro, which includes many familiar names and some penny stocks that may be less familiar. 
    Via Benzinga
    MarketBeat Week in Review – 9/16 - 9/20
    Stocks got a boost as the Federal Reserve cut interest rates, but investors should expect more volatility as economic data continues to deliver mixed signals 
    Via MarketBeat
    Topics Economy
    Exposures Economy Interest Rates

    Performance

    YTD
    -25.88%
    -25.88%
    1 Month
    +16.02%
    +16.02%
    3 Month
    +7.39%
    +7.39%
    6 Month
    -18.54%
    -18.54%
    1 Year
    -29.17%
    -29.17%

    More News

    Read More
    Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
    Via Benzinga
    How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
    Via FinancialNewsMedia
    Galmed Pharmaceuticals Stock Is Soaring Thursday: Here's Why
    Via Benzinga
    US Stocks Mixed; General Mills Posts Upbeat Earnings
    Via Benzinga
    How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
    From FN Media Group LLC
    Via GlobeNewswire
    Why Intuitive Machines Shares Are Trading Higher By Around 41%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Galmed Pharmaceuticals Surges 400%: What's Behind the Explosion?
    Via MarketBeat
    Gold Edges Lower; US Homebuilder Sentiment Rises For September
    Via Benzinga
    Crude Oil Gains Over 1%; US Business Inventories Increase In July
    Via Benzinga
    Exposures Fossil Fuels
    Nasdaq Surges 100 Points; US Retail Sales Beat Estimates
    Via Benzinga
    Topics Earnings
    Exposures Financial
    Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Why Wolfspeed Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Why Keysight Technologies Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Why Mainz Biomed Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    GLMD Stock Earnings: Galmed Pharmaceuticals Reported Results for Q1 2024
    Via InvestorPlace
    Why KKR Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
    Via InvestorPlace
    Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024
    Via InvestorPlace
    Why Esperion Therapeutics Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Why Agenus Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    GLMD Stock Earnings: Galmed Pharmaceuticals Misses EPS for Q4 2023
    Via InvestorPlace
    Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
    Via The Motley Fool
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.